

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

NCT07216482

Status	RECRUITING
Phase	Phase 3
Sponsor	Merck Sharp & Dohme LLC
Enrollment	975 participants

Key Eligibility Criteria

Inclusion (1)

- Has either not received lipid-lowering therapy (LLT) or has not received certain LLTs within a specified time period prior to the study.

Exclusion (8)

- Has a history of homozygous familial hypercholesterolemia (FH), compound heterozygous FH, or double heterozygous FH.
- Had a heart failure hospitalization within 3 months before Screening.
- Is unwilling to take a statin, and/or has a history of statin-associated muscle symptoms or other statin-related AEs to any statin and dose, and/or is known to be intolerant to 1 or more statins.
- Has a history of any of the following conditions: (1) Myopathy, myositis, rhabdomyolysis, or unexplained muscle pain; (2) Muscular or neuromuscular disease; (3) Neuropathy, fibromyalgia, or chronic pain; or (4) Has a personal or family history of hereditary muscular disorders.
- Has active or chronic hepatobiliary or hepatic disease.

... and 3 more (see full listing online)

Locations (88 total)

Central Research Associates (Site 0009), Birmingham, Alabama, United States

G&L Research (Site 0024), Foley, Alabama, United States

Synexus Clinical Research US, Inc. - Phoenix Central (Site 0030), Phoenix, Arizona, United States

... and 85 more locations